When the ESMO Executive Committee decided to launch Annals of Oncology in January of 1989 and appointed me its first Editor-in-Chief, there were probably very few who would have bet on its survival for even a couple of years. Thus, with this issue a decade later, it is with some pride and sense of accomplishment that I relinquish the position of Editor-in-Chief to Prof. David Kerr of Birmingham, UK.
In recent months a number of ESMO members have asked why I did not consider trying to stay on a bit longer notwithstanding the recent establishment of ESMO by-laws specifying a limit of two five-year periods for occupancy by a single individual of the position. Since this rule has only recently gone into effect -and subsequent to my original appointment as editor -a prolongation might have been feasible, but I have not been so inclined. First, I feel that it would not be in the best interest of any major journal for the Editor-in-Chief to remain on the scene too long. Secondly, I feel that I have given to the journal what I had to give and that it is now the turn of someone else to carry it forward. And I feel that David Kerr is the right person for the job.
In retrospect, and with whatever degree of modesty may be due, I believe that under my stewardship the journal has flourished: Annals of Oncology now has a niche among the best of the oncology journals. The numbers of submitted papers, subscribers, pages, etc., are increasing, and the quality of the papers we receive is improving year by year. The journal's financial situation is sound despite our having restricted acceptance of supplements for publication: in fact it would have been easy to increase the journal's margin of profit had we been prepared to compromise on quality.
Most of the numerous comments I receive concerning the journal -directly or indirectly and even by mail, are very positive. Most oncologists feel that Annals of Oncology\s one of the journals, if not the journal, that they read with most pleasure and interest.
However, upon relinquishment of my responsibilities I am not completely satisfied. There are two major concerns. One is related to the impact factor (IF), which for the last couple of years has been approaching, without reaching, 3. In light of the values of some of our competitors with higher IFs, I feel strongly that by now ours should have been closer to 6. I question why we have not yet attained that figure, and wonder whether the simple answer may not be found in 'impactomania', that strange malfunction located somewhere between paranoia and selfishness. In fact, when asked why they had not sent their papers to Annals of Oncology, several authors -especially European -of very good papers have replied candidly that they chose to "send it to a journal with a higher IF." The implication of this syndrome is clear: the system as a whole has a large component of inertia, meaning that once a journal has obtained a high impact factor it will keep it and increase it! And the corollary to this for late-comers is that it is becoming almost impossible to reach the IF which they may in fact deserve.
This problem has been discussed many times within the ESMO: in an effort to achieve a further breakthrough we decided to appeal to the 'European conscience'of our members, without, however, much success: it became apparent that oncologists collectively do not possess such a thing as a 'European conscience'. Of course, the chief culprit is the lethargy of the academic bureaucracy, which evaluates candidates for professorships by the simple total of the IFs of their publications without necessarily going to the extent of actually reading them for assessment of inherent value. And pharmaceutical companies also bear some responsibility for this situation. I could give a number of examples of authors' remarks to the effect that "We would have liked to publish our report in your journal, but the sponsor-company obliged us to choose another one." As demonstrated by the difficulty we have had in attracting advertisers -and this is my second most important concern after 10 years -the pharmaceutical industry does not seem to particularly like our journal. Why? I simply do not know. Frankly, I would have been pleased had the ESMO Executive Committee been a bit tougher with regard to this issue, perhaps by blocking the appearance of 'hostile' companies at the ESMO congress Satellite Symposia, which have become a major market place for the pharmaceutical industry.
I hope that the reader does not gain the impression from these remarks that I leave in dejection, for this is not the case. I am proud that after a decade ESMO is the proprietor of the major European oncology journal, as I am proud of all that my coworkers on the Editorial Committee and I have accomplished in a very difficult environment. On the other hand, I am disappointed in those who declined to place quality and the overall picture before petty interests -who failed as it were to see the forest for the trees.
Finally I would like to extend warmest thanks to the Associate Editors, the members of the Editorial Board and the many other friends who have given us their incredibly helpful support; the Annals of Oncology would have disappeared long since without it. And last but not least, many thanks to the editorial staff members in his efforts to further consolidate the journal's success; Lugano who have been very dedicated, without them, perhaps he will soon even manage to obtain an IF of 6 -and especially without Francesca Frigerio, I could not whatever that may mean, have maintained my almost daily contact with the editorial office. I feel sure that all of them will be similarly F. Cavalli supportive of Prof. Kerr. I wish him all possible luck in Editor-in-Chief
